Dr. Drazer's laboratory research focuses on determining the mechanisms that drive hereditary blood and cancer syndromes, with a particular emphasis on developing "high fidelity" cellular and mouse models of these disorders. He is also involved in the discovery of novel hereditary blood and cancer syndromes. His clinical research is largely focused on optimizing the care of people with hereditary blood and cancer syndromes, including the development of clinical bioinformatics pipelines that improve the diagnosis of patients with these syndromes. He is a member of multiple clinical disease groups at the University of Chicago.
Indiana University
Bloomington
BA, BS - Biochemistry; Biology; English
University of Chicago
Chicago
PhD - Human Genetics
University of Chicago
Chicago
MD - Medicine
University of Chicago
Chicago
Residency - Internal Medicine
University of Chicago
Chicago
Fellowship - Hematology/Oncology
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Treatment of Pleural Mesothelioma: ASCO Guideline Update. J Clin Oncol. 2025 Mar 10; 43(8):1006-1038.
PMID: 39778125
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition.
Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition. Blood. 2024 10 24; 144(17):1765-1780.
PMID: 38991192
FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect.
FLT3 Agonists and Secondary Hematopoietic Malignancies: A Potential Class Effect. Clin Cancer Res. 2024 Jul 15; 30(14):2857-2859.
PMID: 38652676
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297
ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma.
ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma. Ann Surg Oncol. 2024 Jun; 31(6):3785-3786.
PMID: 38502295
ASO Visual Abstract: Venous Thromboembolism in Peritoneal Mesothelioma-Uncovering the Hidden Risk.
ASO Visual Abstract: Venous Thromboembolism in Peritoneal Mesothelioma-Uncovering the Hidden Risk. Ann Surg Oncol. 2024 Mar 08.
PMID: 38457102
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
PMID: 38441062
Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk.
Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk. Ann Surg Oncol. 2024 May; 31(5):3339-3349.
PMID: 38372861
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 02; 22(1):43-69.
PMID: 38394770